Table 2.
Risk of Mortality According to Tumor Stage, Gleason Score, and Treatment (RP+XRT vs XRT+ADT) using Cox Multivariate Analysis
| Cox Proportional Hazards Regression Model Analysis | ||||||
|---|---|---|---|---|---|---|
| Radical Prostatectomy with Adjuvant Radiotherapy |
Radiotherapy and Androgen Deprivation Therapy |
Unadjusted HR (95% CI) |
Adjusted HR (95% CI) |
Adjusted HR (95% CI)a |
Adjusted HR (95% CI)b |
|
| Tumor Stage and Gleason Score |
Event Rate per 1000 | Event Rate per 1000 | ||||
| Prostate Cancer-Specific Mortality | ||||||
| T3aN0M0 | 0.7 | 1.6 | 2.9(1.92,4.36) | 3.82(2.44,5.99) | 4.22(2.83,6.28) | 1.93(1.37,2.71) |
| T3bN0M0 | 2.0 | 2.3 | 1.4(1.03,1.92) | 2.11(1.42,3.12) | 1.84(1.34,2.53) | 1.49(1.02,2.17) |
| T3aN1M0 | 1.5 | 3.2 | 2.46(0.89,6.77) | 14.94(1.96,113.93) | 2.12(0.83,5.41) | NA |
| T3bN1M0 | 3.0 | 4.0 | 1.27(0.58,2.76) | 1.2(0.33,4.29) | 0.98(0.51,1.87) | NA |
| T3aNXM0 | 2.4 | 2.5 | 1.01(0.32,3.23) | 2.07(0.6,7.2) | 1.36(0.32,5.81) | NA |
| T3bNXM0 | 1.8 | 3.0 | 1.9(0.46,7.91) | 2.9(0.62,13.49) | 3.23(0.52,20.22) | NA |
| T4N0M0 | 1.6 | 4.2 | 2.59(1.26,5.33) | 1.48(0.57,3.86) | 2.31(1.05,5.12) | NA |
| T4N1M0 | 2.7 | 7.3 | 2.42(0.68,8.59) | 12.2(1.59,92.49)* | 2.68(0.66,10.9) | NA |
| T4NXM0 | 5.5 | 5.6 | 2.53(0.55,11.75) | 3(0.53,17.1) | 2.13(0.34,13.37) | NA |
| Gleason 5–7 | 1.0 | 1.7 | 2.31(1.65,3.23) | 2.73(1.85,4.01) | 2.62(1.83,3.73) | 2.34(1.20,4.54) |
| Gleason 8–10 | 2.0 | 3.2 | 1.69(1.34,2.14) | 1.99(1.52,2.61) | 1.96(1.53,2.53) | 1.78(1.17,2.71) |
| Overall Mortality | ||||||
| T3aN0M0 | 4.2 | 5.3 | 1.87(1.57,2.22) | 1.69(1.37,2.07) | 1.75(1.45,2.11) | 2.15(1.78,2.61) |
| T3bN0M0 | 5.0 | 5.6 | 1.5(1.24,1.81) | 1.42(1.12,1.79) | 1.49(1.22,1.84) | 1.36(1.08,1.71) |
| T3aN1M0 | 6.8 | 6.6 | 1.11(0.67,1.86) | 1.61(0.73,3.54) | 0.88(0.54,1.44) | NA |
| T3bN1M0 | 6.6 | 7.0 | 1.17(0.69,1.98) | 0.93(0.43,2.05) | 0.74(0.47,1.17) | NA |
| T3aNXM0 | 7.8 | 6.7 | 0.99(0.52,1.88) | 1.26(0.62,2.56) | 0.97(0.40,2.37) | NA |
| T3bNXM0 | 4.1 | 6.8 | 2.03(0.82,5.01) | 2.47(0.92,6.59) | 2.46(0.75,8.05) | NA |
| T4N0M0 | 4.5 | 8.7 | 2.12(1.4,3.22) | 1.59(0.9,2.79) | 1.62(1.00,2.64) | NA |
| T4N1M0 | 7.6 | 8.2 | 0.97(0.43,2.17) | 0.62(0.06,6.21) | 1.06(0.39,2.86) | NA |
| T4NXM0 | 8.1 | 10.0 | 2.97(0.91,9.65) | 2.86(0.75,10.86) | 2.66(0.62,11.45) | NA |
| Gleason 5–7 | 4.2 | 5.1 | 1.77(1.51,2.09) | 1.68(1.38,2.04) | 1.62(1.35,1.96) | 1.34(0.99,1.80) |
| Gleason 8–10 | 5.5 | 7.2 | 1.59(1.38,1.83) | 1.49(1.26,1.76) | 1.33(1.13,1.56) | 1.39(1.08,1.78) |
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; HR, hazard ratio; NA, not available; RP, radical prostatectomy; XRT, radiotherapy.
a
Propensity score weighting method(SMRW) was applied.
b
High dimensional propensity score method was applied. Only men with Part A/Part B coverage 1 year prior cancer diagnosis were included in the analysis. For small samples propensity score can’t be obtained from the logistic regression model.